Piergiuseppe Agostoni

List of Publications by Year
in descending order

366 papers	12,257 citations	26610 56 h-index	48277 88 g-index
374 all docs	374 docs citations	374 times ranked	10744 citing authors

#	Article	IF	Citations
1	Lung Function and Exercise Gas Exchange in Chronic Heart Failure. Circulation, 1997, 96, 2221-2227.	1.6	337
2	Standards for the use of cardiopulmonary exercise testing for the functional evaluation of cardiac patients: a report from the Exercise Physiology Section of the European Association for Cardiovascular Prevention and Rehabilitation. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 249-267.	3.1	308
3	Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis. Circulation, 2018, 138, 1088-1099.	1.6	253
4	Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: Failure of furosemide to provide the same result. American Journal of Medicine, 1994, 96, 191-199.	0.6	241
5	Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. Journal of the American College of Cardiology, 2001, 38, 963-968.	1.2	230
6	Gas diffusion and alveolar-capillary unit in chronic heart failure. European Heart Journal, 2006, 27, 2538-2543.	1.0	209
7	Metabolic exercise test data combined with cardiac and kidney indexes, the MECKI score: A multiparametric approach to heart failure prognosis. International Journal of Cardiology, 2013, 167, 2710-2718.	0.8	183
8	A Long-Term Prognostic Value of Coronary CT Angiography in Suspected Coronary Artery Disease. JACC: Cardiovascular Imaging, 2012, 5, 690-701.	2.3	167
9	Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 3-15.	2.9	157
10	Association of Troponin Levels With Mortality in Italian Patients Hospitalized With Coronavirus Disease 2019. JAMA Cardiology, 2020, 5, 1274.	3.0	157
11	Noninvasive Measurement of Cardiac Output During Exercise by Inert Gas Rebreathing Technique: A New Tool for Heart Failure Evaluation. Journal of the American College of Cardiology, 2005, 46, 1779-1781.	1.2	154
12	Isolated ultrafiltration in moderate congestive heart failure. Journal of the American College of Cardiology, 1993, 21, 424-431.	1.2	146
13	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1899-1913.	1.1	137
14	Improvement of Alveolarâ€“Capillary Membrane Diffusing Capacity With Enalapril in Chronic Heart Failure and Counteracting Effect of Aspirin. Circulation, 1997, 95, 1930-1936.	1.6	133
15	Clinical recommendations for high altitude exposure of individuals with pre-existing cardiovascular conditions. European Heart Journal, 2018, 39, 1546-1554.	1.0	131
16	Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy. American Journal of Medicine, 1996, 101, 461-467.	0.6	128
17	The patient perspective: Quality of life in advanced heart failure with frequent hospitalisations. International Journal of Cardiology, 2015, 191, 256-264.	0.8	125
18	Prevalence, Characteristics, and Outcomes of COVID-19â€“Associated Acute Myocarditis. Circulation, 2022, 145, 1123-1139.	1.6	118

#	Article	IF	Citations
19	Diagnostic Accuracy of Multidetector Computed Tomography Coronary Angiography in Patients With Dilated Cardiomyopathy. Journal of the American College of Cardiology, 2007, 49, 2044-2050.	1.2	117
20	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. European Heart Journal, 2021, 42, 700-710.	1.0	117
21	Continuous Ultrafiltration for Congestive Heart Failure: The CUORE Trial. Journal of Cardiac Failure, 2014, 20, 9-17.	0.7	116
22	Diagnostic Accuracy of Coronary Computed Tomography Angiography. Journal of the American College of Cardiology, 2009, 54, 346-355.	1.2	114
23	Exercise intolerance in chronic heart failure: mechanisms and therapies. Part I. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 637-642.	3.1	107
24	Heart failure and sleep disorders. Nature Reviews Cardiology, 2016, 13, 389-403.	6.1	103
25	Work-rate affects cardiopulmonary exercise test results in heart failure. European Journal of Heart Failure, 2005, 7, 498-504.	2.9	99
26	Impact of heart failure on the clinical course and outcomes of patients hospitalized for <scp>COVID</scp>â€19. Results of the <scp>Cardioâ€COVIDâ€Italy</scp> multicentre study. European Journal of Heart Failure, 2020, 22, 2238-2247.	2.9	99
27	Changes in 24 h ambulatory blood pressure and effects of angiotensin II receptor blockade during acute and prolonged high-altitude exposure: a randomized clinical trial. European Heart Journal, 2014, 35, 3113-3122.	1.0	97
28	Extracorporeal Ultrafiltration for FluidÂOverload in Heart Failure. Journal of the American College of Cardiology, 2017, 69, 2428-2445.	1.2	88
29	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. Thrombosis and Haemostasis, 2021, 121, 1054-1065.	1.8	87
30	Exercise-Induced Pulmonary Edema in Heart Failure. Circulation, 2003, 108, 2666-2671.	1.6	86
31	Usefulness of L-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy. American Journal of Cardiology, 1994, 73, 374-378.	0.7	85
32	Exercise hyperpnea in chronic heart failure: relationships to lung stiffness and expiratory flow limitation. Journal of Applied Physiology, 2002, 92, 1409-1416.	1.2	84
33	Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a longâ€term comparison. European Journal of Heart Failure, 2018, 20, 700-710.	2.9	84
34	Exercise training in patients with ventricular assist devices: a review of the evidence and practical advice. A position paper from the Committee on Exercise Physiology and Training and the Committee of Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 3-13.	2.9	84
35	Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role. European Journal of Heart Failure, 2014, 16, 929-941.	2.9	83
36	Highâ€altitude hypoxia and periodic breathing during sleep: genderâ€related differences. Journal of Sleep Research, 2013, 22, 322-330.	1.7	82

#	Article	IF	Citations
37	Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. American Journal of Cardiology, 1999, 84, 1038-1043.	0.7	78
38	Pulmonary function, cardiac function, and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. American Heart Journal, 1999, 138, 460-467.	1.2	78
39	Lack of improvement of lung diffusing capacity following fluid withdrawal by ultrafiltration in chronic heart failure. Journal of the American College of Cardiology, 2000, 36, 1600-1604.	1.2	75
40	Nifedipine Reduces Pulmonary Pressure and Vascular Tone during Short- but Not Long-term Treatment of Pulmonary Hypertension in Patients with Chronic Obstructive Pulmonary Disease. The American Review of Respiratory Disease, 1989, 139, 120-125.	2.9	74
41	Permanent atrial fibrillation affects exercise capacity in chronic heart failure patients. European Heart Journal, 2008, 29, 2367-2372.	1.0	73
42	Cardiovascular risk assessment in low-resource settings. Journal of Hypertension, 2014, 32, 951-960.	0.3	73
43	Telerehabilitation in heart failure patients: The evidence and the pitfalls. International Journal of Cardiology, 2016, 220, 408-413.	0.8	73
44	Carvedilol Reduces the Inappropriate Increase of Ventilation During Exercise in Heart Failure Patients. Chest, 2002, 122, 2062-2067.	0.4	72
45	Effects of simulated altitude-induced hypoxia on exercise capacity in patients with chronic heart failure. American Journal of Medicine, 2000, 109, 450-455.	0.6	69
46	Lung-heart interaction as a substrate for the improvement in exercise capacity after body fluid volume depletion in moderate congestive heart failure. American Journal of Cardiology, 1995, 76, 793-798.	0.7	66
47	Spironolactone improves lung diffusion in chronic heart failure. European Heart Journal, 2005, 26, 159-164.	1.0	66
48	Impact of chronic obstructive pulmonary disease on exercise ventilatory efficiency in heart failure. International Journal of Cardiology, 2015, 189, 134-140.	0.8	66
49	Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: The CARNEBI trial. International Journal of Cardiology, 2013, 168, 2134-2140.	0.8	65
50	Prognostic Significance and Measurement of Exercise-Derived Hemodynamic Variables in Patients With Heart Failure. Journal of Cardiac Failure, 2007, 13, 672-679.	0.7	64
51	Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: data from the <scp>MECKI</scp> Score Research Group. European Journal of Heart Failure, 2016, 18, 545-553.	2.9	64
52	â€œYou can leave your mask onâ€• effects on cardiopulmonary parameters of different airway protective masks at rest and during maximal exercise. European Respiratory Journal, 2021, 58, 2004473.	3.1	64
53	How to perform and report a cardiopulmonary exercise test in patients with chronic heart failure. International Journal of Cardiology, 2019, 288, 107-113.	0.8	63
54	The Prognostic Value of Normal Stress Cardiac Magnetic Resonance in Patients With Known or Suspected Coronary Artery Disease. Circulation: Cardiovascular Imaging, 2013, 6, 574-582.	1.3	61

#	Article	IF	Citations
55	Prognostic Value of Indeterminable Anaerobic Threshold in Heart Failure. Circulation: Heart Failure, 2013, 6, 977-987.	1.6	60
56	Ambulatory Blood Pressure in Untreated and Treated Hypertensive Patients at High Altitude. Hypertension, 2015, 65, 1266-1272.	1.3	60
57	Heart failure prognosis over time: how the prognostic role of oxygen consumption and ventilatory efficiency during exercise has changed in the last 20 years. European Journal of Heart Failure, 2019, 21, 208-217.	2.9	60
58	Cardiomegaly as a possible cause of lung dysfunction in patients with heart failure. American Heart Journal, 2000, 140, A17-A21.	1.2	58
59	Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. European Heart Journal, 2005, 26, 481-488.	1.0	56
60	Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure. Journal of Cardiovascular Medicine, 2011, 12, 76-84.	0.6	56
61	Exercise testing in the clinical management of patients affected by pulmonary arterial hypertension. European Journal of Preventive Cardiology, 2012, 19, 960-971.	0.8	55
62	Lung function with carvedilol and bisoprolol in chronic heart failure: Is Î² selectivity relevant?. European Journal of Heart Failure, 2007, 9, 827-833.	2.9	54
63	Exertional dyspnoea in chronic heart failure: the role of the lung and respiratory mechanical factors. European Respiratory Review, 2016, 25, 317-332.	3.0	54
64	Prognostic Benefit of Cardiac Magnetic Resonance Over Transthoracic Echocardiography for the Assessment of Ischemic and Nonischemic Dilated Cardiomyopathy Patients Referred for the Evaluation of Primary Prevention Implantable Cardioverterâ€“Defibrillator Therapy. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	54
65	Effect of non-insulin-dependent diabetes mellitus on pulmonary function and exercise tolerance in chronic congestive heart failure. American Journal of Cardiology, 2002, 89, 191-197.	0.7	53
66	The role of cardiopulmonary exercise tests in pulmonary arterial hypertension. European Respiratory Review, 2018, 27, 170134.	3.0	53
67	Effects of Slow Deep Breathing at High Altitude on Oxygen Saturation, Pulmonary and Systemic Hemodynamics. PLoS ONE, 2012, 7, e49074.	1.1	51
68	Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy. Heart, 2016, 102, 602-609.	1.2	50
69	Comparison of Changes in Respiratory Function and Exercise Oxygen Uptake With Losartan Versus Enalapril in Congestive Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 1997, 80, 1572-1576.	0.7	49
70	Effects of rapid saline infusion on lung mechanics and airway responsiveness in humans. Journal of Applied Physiology, 2003, 95, 728-734.	1.2	49
71	Oxidized proteins in plasma of patients with heart failure: Role in endothelial damage. European Journal of Heart Failure, 2008, 10, 244-251.	2.9	49
72	Exercise intolerance in chronic heart failure: mechanisms and therapies. Part II. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 643-648.	3.1	49

#	Article	IF	Citations
73	Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. Journal of Cardiovascular Pharmacology, 2020, 76, 4-22.	0.8	49
74	Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors. American Heart Journal, 1999, 138, 254-260.	1.2	48
75	Does lung diffusion impairment affect exercise capacity in patients with heart failure?. British Heart Journal, 2002, 88, 453-459.	2.2	48
76	Carvedilol reduces exercise-induced hyperventilation: A benefit in normoxia and a problem with hypoxia. European Journal of Heart Failure, 2006, 8, 729-735.	2.9	48
77	Prognostic Stratification of Patients With ST-Segmentâ€“Elevation Myocardial Infarction (PROSPECT). Circulation: Cardiovascular Imaging, 2017, 10, .	1.3	48
78	Long-Term Effectiveness of Cardiac Resynchronization Therapy in Heart Failure Patients With Unfavorable Cardiac Veins Anatomy. Journal of the American College of Cardiology, 2011, 58, 483-490.	1.2	47
79	Sex and Acetazolamide Effects on Chemoreflex and Periodic Breathing During Sleep at Altitude. Chest, 2015, 147, 120-131.	0.4	46
80	High-altitude exposure of three weeks duration increases lung diffusing capacity in humans. Journal of Applied Physiology, 2011, 110, 1564-1571.	1.2	45
81	Coronary In-Stent Restenosis: Assessment with CT Coronary Angiography. Radiology, 2012, 265, 410-417.	3.6	45
82	Chronotropic Incompentence and Functional Capacity in Chronic Heart Failure: No Role of Î²â€Blockers and Î²â€Blocker Dose. Cardiovascular Therapeutics, 2012, 30, 100-108.	1.1	45
83	Sixty-Fourâ€“Slice Multidetector Computed Tomography. Circulation: Cardiovascular Imaging, 2009, 2, 199-205.	1.3	44
84	Cardiovascular mortality and chronotropic incompetence in systolic heart failure: the importance of a reappraisal of current cutâ€off criteria. European Journal of Heart Failure, 2014, 16, 201-209.	2.9	44
85	Evaluation of Breathlessness in Asbestos Workers. The American Review of Respiratory Disease, 1987, 135, 812-816.	2.9	43
86	Impeded Alveolar-Capillary Gas Transfer With Saline Infusion in Heart Failure. Hypertension, 1999, 34, 1202-1207.	1.3	42
87	Exercise response after rapid intravenous infusion of saline in healthy humans. Journal of Applied Physiology, 2004, 97, 697-703.	1.2	42
88	Effect of biventricular pacing on ventilatory and perceptual responses to exercise in patients with stable chronic heart failure. Journal of Applied Physiology, 2009, 106, 1574-1583.	1.2	42
89	Effects of Î²-blockers on ventilation efficiency in heart failure. American Heart Journal, 2010, 159, 1067-1073.	1.2	42
90	A Long-Term Prognostic Value of CT Angiography and Exercise ECG in Patients With Suspected CAD. JACC: Cardiovascular Imaging, 2013, 6, 641-650.	2.3	42

#	Article	IF	Citations
91	Acute high-altitude exposure reduces lung diffusion: Data from the HIGHCARE Alps project. Respiratory Physiology and Neurobiology, 2013, 188, 223-228.	0.7	42
92	A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. International Journal of Cardiology, 2019, 297, 83-90.	0.8	42
93	Heart Failure Progression in Hypertrophic Cardiomyopathyã€€â€“ Possible Insights From Cardiopulmonary Exercise Testing â€“. Circulation Journal, 2016, 80, 2204-2211.	0.7	41
94	The Role of Gas Exchange Variables in Cardiopulmonary Exercise Testing for Risk Stratification and Management of Heart Failure with Reduced Ejection Fraction. American Heart Journal, 2018, 202, 116-126.	1.2	41
95	Relationship of resting hemoglobin concentration to peak oxygen uptake in heart failure patients. American Journal of Hematology, 2010, 85, 414-417.	2.0	40
96	Physiological insights of exercise hyperventilation in arterial and chronic thromboembolic pulmonary hypertension. International Journal of Cardiology, 2018, 259, 178-182.	0.8	40
97	Rationale and design of the EMPERIALâ€Preserved and EMPERIALâ€Reduced trials of empagliflozin in patients with chronic heart failure. European Journal of Heart Failure, 2019, 21, 932-942.	2.9	40
98	Management of Osteoarthritis: Expert Opinion on NSAIDs. Pain and Therapy, 2021, 10, 783-808.	1.5	40
99	Mechanisms of Periodic Breathing During Exercise in Patients With Chronic Heart Failure. Chest, 2008, 133, 197-203.	0.4	39
100	Lvad pump speed increase is associated with increased peak exercise cardiac output and vo2, postponed anaerobic threshold and improved ventilatory efficiency. International Journal of Cardiology, 2017, 230, 28-32.	0.8	39
101	RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. Vascular Pharmacology, 2020, 135, 106805.	1.0	39
102	A Non Invasive Estimate of Dead Space Ventilation from Exercise Measurements. PLoS ONE, 2014, 9, e87395.	1.1	39
103	Changes in Subendocardial Viability Ratio With Acute High-Altitude Exposure and Protective Role of Acetazolamide. Hypertension, 2013, 61, 793-799.	1.3	38
104	Prognostic value of dipyridamole stress cardiac magnetic resonance in patients with known or suspected coronary artery disease: a mid-term follow-up study. European Radiology, 2016, 26, 2155-2165.	2.3	38
105	Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. Journal of Clinical Pharmacology, 2017, 57, 440-451.	1.0	38
106	Cardiopulmonary interaction in heart failure. Pulmonary Pharmacology and Therapeutics, 2007, 20, 130-134.	1.1	37
107	Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. Cardiac Failure Review, 2020, 6, e19.	1.2	37
108	The metabolic exercise test data combined with Cardiac And Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study. International Journal of Cardiology, 2016, 203, 1067-1072.	0.8	36

#	Article	IF	Citations
109	Reference Values for Peak Exercise Cardiac Output in Healthy Individuals. Chest, 2017, 151, 1329-1337.	0.4	36
110	A Machine Learning Approach for Mortality Prediction in COVID-19 Pneumonia: Development and Evaluation of the Piacenza Score. Journal of Medical Internet Research, 2021, 23, e29058.	2.1	36
111	Erectile Dysfunction in Heart Failure: Correlation with Severity, Exercise Performance, Comorbidities, and Heart Failure Treatment. Journal of Sexual Medicine, 2009, 6, 2795-2805.	0.3	35
112	Oxygen Transport to Muscle During Exercise in Chronic Congestive Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy. American Journal of Cardiology, 1997, 79, 1120-1124.	0.7	34
113	Sustained Benefit from Ultrafiltration in Moderate Congestive Heart Failure. Cardiology, 2001, 96, 183-189.	0.6	34
114	Lungs in Heart Failure. Pulmonary Medicine, 2012, 2012, 1-9.	0.5	34
115	Prognostic Value of Multidetector Computed Tomography Coronary Angiography in Diabetes. Diabetes Care, 2013, 36, 1834-1841.	4.3	34
116	Acetazolamide and Inhaled Carbon Dioxide Reduce Periodic Breathing During Exercise in Patients With Chronic Heart Failure. Journal of Cardiac Failure, 2014, 20, 278-288.	0.7	34
117	Role of comorbidities in heart failure prognosis Part 2: Chronic kidney disease, elevated serum uric acid. European Journal of Preventive Cardiology, 2020, 27, 35-45.	0.8	34
118	Implications of atrial fibrillation on the clinical course and outcomes of hospitalized COVID-19 patients: results of the Cardio-COVID-Italy multicentre study. Europace, 2021, 23, 1603-1611.	0.7	34
119	Angiotensin-converting enzyme inhibition facilitates alveolar-capillary gas transfer and improves ventilation-perfusion coupling in patients with left ventricular dysfunction. Clinical Pharmacology and Therapeutics, 1999, 65, 319-327.	2.3	33
120	Hemodynamic Effects of Exercise Training in Heart Failure. Journal of Cardiac Failure, 2011, 17, 916-922.	0.7	33
121	Heart failure and anemia: Effects on prognostic variables. European Journal of Internal Medicine, 2017, 37, 56-63.	1.0	33
122	Comprehensive effects of left ventricular assist device speed changes on alveolar gas exchange, sleep ventilatory pattern, and exercise performance. Journal of Heart and Lung Transplantation, 2018, 37, 1361-1371.	0.3	33
123	Circulating Plasma Surfactant Protein Type B as Biological Marker of Alveolar-Capillary Barrier Damage in Chronic Heart Failure. Circulation: Heart Failure, 2009, 2, 175-180.	1.6	32
124	Surfactant-Derived Proteins as Markers of Alveolar Membrane Damage in Heart Failure. PLoS ONE, 2014, 9, e115030.	1.1	32
125	Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation. European Journal of Preventive Cardiology, 2015, 22, 1046-1055.	0.8	32
126	Exercise programs for LVAD supported patients: A snapshot from the ESC affiliated countries. International Journal of Cardiology, 2015, 201, 215-219.	0.8	32

#	Article	IF	Citations
127	Pulmonary embolism in patients with COVID-19: characteristics and outcomes in the Cardio-COVID Italy multicenter study. Clinical Research in Cardiology, 2021, 110, 1020-1028.	1.5	32
128	Modulation of alveolar-capillary sodium handling as a mechanism of protection of gas transfer by enalapril, and not by losartan, in chronic heart failure. Journal of the American College of Cardiology, 2001, 37, 398-406.	1.2	31
129	Surfactant protein B and RAGE increases in the plasma during cardiopulmonary bypass: a pilot study. European Respiratory Journal, 2011, 37, 841-847.	3.1	30
130	Effects of Betaâ€Blockade on Exercise Performance at High Altitude: A Randomized, Placeboâ€Controlled Trial Comparing the Efficacy of Nebivolol versus Carvedilol in Healthy Subjects. Cardiovascular Therapeutics, 2012, 30, 240-248.	1.1	30
131	Prognostic value of cardiopulmonary exercise testing in Idiopathic Dilated Cardiomyopathy. International Journal of Cardiology, 2016, 223, 596-603.	0.8	30
132	Renal Function and Peak Exercise Oxygen Consumption in Chronic Heart Failure With Reduced Left Ventricular Ejection Fraction. Circulation Journal, 2015, 79, 583-591.	0.7	29
133	Qualitative and quantitative evaluation of a new wearable device for ECG and respiratory Holter monitoring. International Journal of Cardiology, 2018, 272, 231-237.	0.8	29
134	SARS-CoV-2 spread in Northern Italy: what about the pollution role?. Environmental Monitoring and Assessment, 2020, 192, 325.	1.3	29
135	Role of Alveolar Î²2-Adrenergic Receptors on Lung Fluid Clearance and Exercise Ventilation in Healthy Humans. PLoS ONE, 2013, 8, e61877.	1.1	29
136	The Discriminatory Value of the P(A-a)O2 during Exercise in the Detection of Asbestosis in Asbestos Exposed Workers. Chest, 1989, 95, 52-55.	0.4	28
137	A Four-Minute Submaximal Constant Work Rate Exercise Test to Assess Cardiovascular Functional Class in Chronic Heart Failure. American Journal of Cardiology, 1998, 81, 1210-1214.	0.7	28
138	Prognostic role of Î²â€blocker selectivity and dosage regimens in heart failure patients. Insights from the <scp>MECKI</scp> score database. European Journal of Heart Failure, 2017, 19, 904-914.	2.9	28
139	Pro-oxidant and pro-inflammatory effects of glycated albumin on cardiomyocytes. Free Radical Biology and Medicine, 2019, 144, 245-255.	1.3	28
140	N-Acetyl-Cysteine Regenerates Albumin Cys34 by a Thiol-Disulfide Breaking Mechanism: An Explanation of Its Extracellular Antioxidant Activity. Antioxidants, 2020, 9, 367.	2.2	28
141	Exercise-induced hemoconcentration in heart failure due to dilated cardiomyopathy. American Journal of Cardiology, 1999, 83, 278-280.	0.7	27
142	Noninvasive Cardiac Output Measurement by Inert Gas Rebreathing in Suspected Pulmonary Hypertension. American Journal of Cardiology, 2014, 113, 546-551.	0.7	27
143	Effects of hypobaric hypoxia exposure at high altitude on left ventricular twist in healthy subjects: data from HIGHCARE study on Mount Everest. European Heart Journal Cardiovascular Imaging, 2016, 17, 635-643.	0.5	27
144	Cardiac implantable electronic devices with a defibrillator component and allâ€cause mortality in left ventricular assist device carriers: results from the PCHFâ€VAD registry. European Journal of Heart Failure, 2019, 21, 1129-1141.	2.9	27

#	Article	IF	Citations
145	Cardiac and Renal Dysfunction in Chronic Heart Failure: Relation to Neurohumoral Activation and Prognosis. American Journal of the Medical Sciences, 2001, 321, 359-366.	0.4	26
146	Continuous positive airway pressure increases haemoglobin O2 saturation after acute but not prolonged altitude exposure. European Heart Journal, 2010, 31, 457-463.	1.0	26
147	COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2021, 117, 2148-2160.	1.8	26
148	Angiotensin-converting enzyme inhibition restores the diffusing capacity for carbon monoxide in patients with chronic heart failure by improving the molecular diffusion across the alveolar capillary membrane. Clinical Science, 1999, 96, 17-22.	1.8	25
149	End-tidal pressure of CO2 and exercise performance in healthy subjects. European Journal of Applied Physiology, 2008, 103, 727-732.	1.2	25
150	High diagnostic accuracy of prospective ECG-gating 64-slice computed tomography coronary angiography for the detection of in-stent restenosis. European Radiology, 2011, 21, 1430-1438.	2.3	25
151	Severe heart failure prognosis evaluation for transplant selection in the era of beta-blockers: Role of peak oxygen consumption. International Journal of Cardiology, 2013, 168, 5078-5081.	0.8	25
152	Ischemic changes in exercise ECG in a hypertensive subject acutely exposed to high altitude. Possible role of a high-altitude induced imbalance in myocardial oxygen supplyâ€“demand. International Journal of Cardiology, 2014, 171, e100-e102.	0.8	25
153	Exercise prescription for the prevention and treatment of cardiovascular diseases: part I. Journal of Cardiovascular Medicine, 2008, 9, 529-544.	0.6	24
154	Index Measured at an Intermediate Altitude to Predict Impending Acute Mountain Sickness. Medicine and Science in Sports and Exercise, 2011, 43, 1811-1818.	0.2	24
155	Exercise oscillatory ventilation and prognosis in heart failure patients with reduced and midâ€range ejection fraction. European Journal of Heart Failure, 2019, 21, 1586-1595.	2.9	24
156	Additional clinical role of 64-slice multidetector computed tomography in the evaluation of coronary artery variants and anomalies. International Journal of Cardiology, 2010, 145, 388-390.	0.8	23
157	Redox Proteomics Identification of Oxidatively Modified Myocardial Proteins in Human Heart Failure: Implications for Protein Function. PLoS ONE, 2012, 7, e35841.	1.1	23
158	Gender and age normalization and ventilation efficiency during exercise in heart failure with reduced ejection fraction. ESC Heart Failure, 2020, 7, 368-377.	1.4	23
159	Prognostic role of transferrin saturation in heart failure patients. European Journal of Preventive Cardiology, 2021, 28, 1639-1646.	0.8	23
160	Accessory Thyroid Tissue in the Right Ventricle. Chest, 1989, 96, 424-425.	0.4	22
161	Plasma bradykinin levels in human chronic congestive heart failure. Clinical Science, 2000, 99, 461-466.	1.8	22
162	Severe cardiomyopathy in a young patient with complete deficiency of adipose triglyceride lipase due to a novel mutation in PNPLA2 gene. International Journal of Cardiology, 2016, 207, 165-167.	0.8	22

#	Article	IF	Citations
163	Anaerobic Threshold and Respiratory Compensation Point Identification During Cardiopulmonary Exercise Tests in Chronic Heart Failure. Chest, 2019, 156, 338-347.	0.4	22
164	Cardiopulmonary evidence of exercise-induced silent ischaemia. European Journal of Cardiovascular Prevention and Rehabilitation, 2006, 13, 249-253.	3.1	21
165	Respiratory Effects of Î²-blocker Therapy in Heart Failure. Cardiovascular Drugs and Therapy, 2009, 23, 377-384.	1.3	21
166	Levosimendan improves exercise performance in patients with advanced chronic heart failure. ESC Heart Failure, 2015, 2, 133-141.	1.4	21
167	Exercise Performance Is a Prognostic Indicator in Elderly Patients With Chronic Heart Failureã€€â€“ Application of Metabolic Exercise Cardiac Kidney Indexes Score â€“. Circulation Journal, 2015, 79, 2608-2615.	0.7	21
168	Surfactant protein B: From biochemistry to its potential role as diagnostic and prognostic marker in heart failure. International Journal of Cardiology, 2016, 221, 456-462.	0.8	21
169	Late onset of neutral lipid storage disease due to novel PNPLA2 mutations causing total loss of lipase activity in a patient with myopathy and slight cardiac involvement. Neuromuscular Disorders, 2017, 27, 481-486.	0.3	21
170	Cardiac patient care during a pandemic: how to reorganise a heart failure unit at the time of COVID-19. European Journal of Preventive Cardiology, 2020, 27, 1127-1132.	0.8	21
171	Interleukin-1Î² levels predict long-term mortality and need for heart transplantation in ambulatory patients affected by idiopathic dilated cardiomyopathy. Oncotarget, 2017, 8, 25131-25140.	0.8	21
172	Lateral Decubitus Position Generates Discomfort and Worsens Lung Function in Chronic Heart Failure. Chest, 2005, 128, 1511-1516.	0.4	20
173	Disappearance of isocapnic buffering period during increasing work rate exercise at high altitude. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 354-358.	3.1	20
174	Alveolar Membrane Conductance Decreases as BNP Increases During Exercise in Heart Failure. Rationale for BNP in the Evaluation of Dyspnea. Journal of Cardiac Failure, 2009, 15, 136-144.	0.7	20
175	Comparison of the diagnostic performance of 64-slice computed tomography coronary angiography in diabetic and non-diabetic patients with suspected coronary artery disease. Cardiovascular Diabetology, 2010, 9, 80.	2.7	20
176	Diagnostic performance of two types of low radiation exposure protocol for prospective ECG-triggering multidetector computed tomography angiography in assessment of coronary artery bypass graft. International Journal of Cardiology, 2012, 157, 63-69.	0.8	20
177	Periodic Breathing during Incremental Exercise. Annals of the American Thoracic Society, 2017, 14, S116-S122.	1.5	20
178	Prognostic Role of Cardiopulmonary Exercise Testing in Clinical Practice. Annals of the American Thoracic Society, 2017, 14, S53-S58.	1.5	20
179	Contribution of central and peripheral factors at peak exercise in heart failure patients with progressive severity of exercise limitation. International Journal of Cardiology, 2017, 248, 252-256.	0.8	20
180	Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study. Frontiers in Medicine, 2021, 8, 639970.	1.2	20

#	Article	IF	Citations
181	Prognostic Value of Peak Oxygen Uptake in Patients Supported With Left Ventricular Assist Devices (PRO-VAD). JACC: Heart Failure, 2021, 9, 758-767.	1.9	20
182	Predicted values of exercise capacity in heart failure: where we are, where to go. Heart Failure Reviews, 2014, 19, 645-653.	1.7	19
183	Sex Profile and Risk Assessment With Cardiopulmonary Exercise Testing in Heart Failure: Propensity Score Matching for Sex Selection Bias. Canadian Journal of Cardiology, 2016, 32, 754-759.	0.8	19
184	Clinical and prognostic impact of chronotropic incompetence in patients with hypertrophic cardiomyopathy. International Journal of Cardiology, 2018, 271, 125-131.	0.8	19
185	The influence of diastolic and systolic function on exercise performance in heart failure due to dilated cardiomyopathy or ischemic heart disease. European Journal of Heart Failure, 1999, 1, 161-167.	2.9	18
186	Influence of exertional oscillatory ventilation on exercise performance in heart failure. European Journal of Cardiovascular Prevention and Rehabilitation, 2008, 15, 688-692.	3.1	18
187	Determinants of peak oxygen uptake in patients with hypertrophic cardiomyopathy: a single-center study. Internal and Emergency Medicine, 2014, 9, 293-302.	1.0	18
188	Mechanisms That Modulate Peripheral Oxygen Delivery during Exercise in Heart Failure. Annals of the American Thoracic Society, 2017, 14, S40-S47.	1.5	18
189	Anemia and Iron Deficiency in Heart Failure. Heart Failure Clinics, 2019, 15, 359-369.	1.0	18
190	Exercise physiology in pulmonary hypertension patients with and without congenital heart disease. European Journal of Preventive Cardiology, 2019, 26, 86-93.	0.8	18
191	Systemic to Pulmonary Bronchial Blood Flow in Heart Failure. Chest, 1995, 107, 1247-1252.	0.4	17
192	Noninvasive Measurement of Cardiac Output During Exercise by Inert Gas Rebreathing Technique. Heart Failure Clinics, 2009, 5, 209-215.	1.0	17
193	Evaluation of noninvasive exercise cardiac output determination in chronic heart failure patients: a proposal of a new diagnostic and prognostic method. Journal of Cardiovascular Medicine, 2011, 12, 19-27.	0.6	17
194	Evolution of the concept of ventilatory limitation during exercise. Combining the pneumologist and cardiologist point of view. Respiratory Physiology and Neurobiology, 2011, 179, 127-128.	0.7	17
195	The Effects of Anesthesia, Muscle Paralysis, and Ventilation on the Lung Evaluated by Lung Diffusion for Carbon Monoxide and Pulmonary Surfactant Protein B. Anesthesia and Analgesia, 2015, 120, 373-380.	1.1	17
196	Risk stratification in cardiomyopathy. European Journal of Preventive Cardiology, 2020, 27, 52-58.	0.8	17
197	S-Thiolation Targets Albumin in Heart Failure. Antioxidants, 2020, 9, 763.	2.2	17
198	Postâ€discharge arrhythmic risk stratification of patients with acute myocarditis and lifeâ€threatening ventricular tachyarrhythmias. European Journal of Heart Failure, 2021, 23, 2045-2054.	2.9	17

#	Article	IF	Citations
199	Inspired Gas Relative Humidity Affects Systemic to Pulmonary Bronchial Blood Flow in Humans. Chest, 1990, 97, 1377-1380.	0.4	16
200	Impaired bradykinin response to ischaemia and exercise in patients with mild congestive heart failure during angiotensin-converting enzyme treatment. Relationships with endothelial function, coagulation and inflammation. British Journal of Haematology, 2005, 130, 113-120.	1.2	16
201	Alveolarâ€“capillary membrane diffusion measurement by nitric oxide inhalation in heart failure. European Journal of Preventive Cardiology, 2015, 22, 206-212.	0.8	16
202	Prognostic role of atrial fibrillation in patients affected by chronic heart failure. Data from the MECKI score research group. European Journal of Internal Medicine, 2015, 26, 515-520.	1.0	16
203	Blood pressure response to six-minute walk test in hypertensive subjects exposed to high altitude: effects of antihypertensive combination treatment. International Journal of Cardiology, 2016, 219, 27-32.	0.8	16
204	Temperature dependence of intraparenchymal bronchial blood flow. Respiration Physiology, 1987, 68, 259-267.	2.8	15
205	Pleural liquid pressure in the zone of apposition and in the lung zone. Respiration Physiology, 1989, 75, 357-370.	2.8	15
206	Noninvasive Cardiac Output Measurement: A New Tool in Heart Failure. Cardiology, 2009, 114, 244-246.	0.6	15
207	Peripheral Adaptation Mechanisms in Physical Training and Cardiac Rehabilitation: The Case of a Patient Supported by a Cardiowest Total Artificial Heart. Journal of Cardiac Failure, 2011, 17, 670-675.	0.7	15
208	Cardiopulmonary Exercise Testing in Patients with Heart Failure with Specific Comorbidities. Annals of the American Thoracic Society, 2017, 14, S110-S115.	1.5	15
209	Increased serum uric acid level predicts poor prognosis in mildly severe chronic heart failure with reduced ejection fraction. An analysis from the MECKI score research group. European Journal of Internal Medicine, 2020, 72, 47-52.	1.0	15
210	How Patients With Heart Failure Perform Daily Life Activities. Circulation: Heart Failure, 2020, 13, e007503.	1.6	15
211	Risk Stratification in Hypertrophic Cardiomyopathy. Insights from Genetic Analysis and Cardiopulmonary Exercise Testing. Journal of Clinical Medicine, 2020, 9, 1636.	1.0	15
212	Cardiopulmonary exercise testing for heart failure patients: a hodgepodge of techniques, parameters and interpretations. In other words, the need for a time-breakThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2006, 27, 633-634.	1.0	14
213	Sildenafil improves the alveolarâ€“capillary function in heart failure patients. International Journal of Cardiology, 2008, 126, 68-72.	0.8	14
214	Assessment of cardiac resynchronization therapy response. International Journal of Cardiology, 2009, 136, 240-242.	0.8	14
215	Do Maximum Flow-Volume Loops Collected During Maximum Exercise Test Alter the Main Cardiopulmonary Parameters?. Chest, 2009, 135, 425-433.	0.4	14
216	Rationale for cardiopulmonary exercise test in the assessment of surgical risk. Journal of Cardiovascular Medicine, 2013, 14, 254-261.	0.6	14

#	Article	IF	Citations
217	Coronary stent evaluation with coronary computed tomographic angiography: Comparison between low-osmolar, high-iodine concentration iomeprol-400 and iso-osmolar, lower-iodine concentration iodixanol-320. Journal of Cardiovascular Computed Tomography, 2014, 8, 44-51.	0.7	14
218	Plasma immature form of surfactant protein type B correlates with prognosis in patients with chronic heart failure. A pilot single-center prospective study. International Journal of Cardiology, 2015, 201, 394-399.	0.8	14
219	Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133+ cells in ischemic refractory cardiomyopathy trial (RECARDIO). Stem Cell Research and Therapy, 2018, 9, 235.	2.4	14
220	Regional differences in exercise training implementation in heart failure: findings from the Exercise Training in Heart Failure (ExTraHF) survey. European Journal of Heart Failure, 2019, 21, 1142-1148.	2.9	14
221	Prognostic impact of admission high-sensitivity C-reactive protein in acute myocardial infarction patients with and without diabetes mellitus. Cardiovascular Diabetology, 2020, 19, 183.	2.7	14
222	Choosing among Î²-blockers in heart failure patients according to Î²-receptorsâ€™ location and functions in the cardiopulmonary system. Pharmacological Research, 2020, 156, 104785.	3.1	14
223	Combined Role of Troponin and Natriuretic Peptides Measurements in Patients With Covid-19 (from the) Tj ETQq1 1 0.784314 rgBT /Ov	0.7	14
224	Modulation of the Atrioventricular Node Conduction to Achieve Rate Control in Patients with Atrial Fibrillation: Long-Term Results. PACE - Pacing and Clinical Electrophysiology, 1999, 22, 442-452.	0.5	13
225	Angiotensin-converting enzyme inhibition restores the diffusing capacity for carbon monoxide in patients with chronic heart failure by improving the molecular diffusion across the alveolar capillary membrane. Clinical Science, 1999, 96, 17.	1.8	13
226	Considerations on Safety and Treatment of Patients with Chronic Heart Failure at High Altitude. High Altitude Medicine and Biology, 2013, 14, 96-100.	0.5	13
227	Acute Increase of CardiacÂOutput Reduces Central Sleep Apneas in Heart Failure Patients. Journal of the American College of Cardiology, 2015, 66, 2571-2572.	1.2	13
228	Effects of Blood Transfusion on Exercise Capacity in Thalassemia Major Patients. PLoS ONE, 2015, 10, e0127553.	1.1	13
229	Mineralocorticoid receptor antagonists for heart failure: a realâ€life observational study. ESC Heart Failure, 2018, 5, 267-274.	1.4	13
230	Exercise gas exchange in continuous-flow left ventricular assist device recipients. PLoS ONE, 2018, 13, e0187112.	1.1	13
231	Dose-dependent efficacy of Î²-blocker in patients with chronic heart failure and atrial fibrillation. International Journal of Cardiology, 2018, 273, 141-146.	0.8	13
232	Long-term prognostic role of diabetes mellitus and glycemic control in heart failure patients with reduced ejection fraction. International Journal of Cardiology, 2020, 317, 103-110.	0.8	13
233	Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan. Cardiac Failure Review, 2019, 5, 155-161.	1.2	13
234	Brisk walking can be a maximal effort in heart failure patients: a comparison of cardiopulmonary exercise and 6Âmin walking test cardiorespiratory data. ESC Heart Failure, 2022, 9, 812-821.	1.4	13

#	Article	IF	Citations
235	Exercise capacity in patients with beta-thalassaemia intermedia. British Journal of Haematology, 2005, 131, 278-281.	1.2	12
236	Effect of Acute Î²-blocker Withholding on Ventilatory Efficiency in Patients With Advanced Chronic Heart Failure. Journal of Cardiac Failure, 2010, 16, 548-555.	0.7	12
237	Kinetics of plasma SPB and RAGE during mechanical ventilation in patients undergoing major vascular surgery. Respiratory Physiology and Neurobiology, 2011, 178, 256-260.	0.7	12
238	Blood Pressure Response to Exercise in Hypertensive Subjects Exposed to High Altitude and Treatment Effects. Journal of the American College of Cardiology, 2015, 66, 2806-2807.	1.2	12
239	Reninâ€“Angiotensinâ€“Aldosterone System Is Not Involved in the Arterial Stiffening Induced by Acute and Prolonged Exposure to High Altitude. Hypertension, 2017, 70, 75-84.	1.3	12
240	Surfactant proteins changes after acute hemodynamic improvement in patients with advanced chronic heart failure treated with Levosimendan. Respiratory Physiology and Neurobiology, 2018, 252-253, 47-51.	0.7	12
241	Isocapnic buffering period: From physiology to clinics. European Journal of Preventive Cardiology, 2019, 26, 1107-1114.	0.8	12
242	Comparison between PtCO2 and PaCO2 and Derived Parameters in Heart Failure Patients during Exercise: A Preliminary Study. Sensors, 2021, 21, 6666.	2.1	12
243	Increase of Alveolar Pressure Reduces Systemic-to-Pulmonary Bronchial Blood Flow in Humans. Chest, 1989, 96, 1081-1085.	0.4	11
244	Pleural pressure from abdominal to pulmonary rib cage: sweep of the lung border. Respiration Physiology, 1989, 75, 105-115.	2.8	11
245	Doppler assessment of left ventricular filling pattern in silent ischemia in patients with Prinzmetal's angina. American Journal of Cardiology, 1990, 66, 1055-1059.	0.7	11
246	Plasma bradykinin levels in human chronic congestive heart failure. Clinical Science, 2000, 99, 461.	1.8	11
247	Imaging of cardiac venous system in patients with dilated cardiomyopathy by 64-slice computed tomography: Comparison between non-ischemic and ischemic etiology. International Journal of Cardiology, 2010, 144, 340-343.	0.8	11
248	The alveolar to arterial oxygen partial pressure difference is associated with pulmonary diffusing capacity in heart failure patients. Respiratory Physiology and Neurobiology, 2016, 233, 1-6.	0.7	11
249	Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction. Journal of Cardiovascular Medicine, 2020, 21, 882-888.	0.6	11
250	The MECKI score initiative: Development and state of the art. European Journal of Preventive Cardiology, 2020, 27, 5-11.	0.8	11
251	Non-invasive estimation of stroke volume during exercise from oxygen in heart failure patients. European Journal of Preventive Cardiology, 2021, 28, 280-286.	0.8	11
252	Old and new equations for maximal heart rate prediction in patients with heart failure and reduced ejection fraction on beta-blockers treatment: results from the MECKI score data set. European Journal of Preventive Cardiology, 2022, 29, 1680-1688.	0.8	11

#	Article	IF	Citations
253	Serum to urinary sodium concentration ratio is an estimate of plasma renin activity in congestive heart failure. European Journal of Heart Failure, 2002, 4, 597-603.	2.9	10
254	Exercise prescription for the prevention and treatment of cardiovascular diseases: part II. Journal of Cardiovascular Medicine, 2008, 9, 641-652.	0.6	10
255	Contribution of Î²-adrenergic receptors to exercise-induced bronchodilatation in healthy humans. Respiratory Physiology and Neurobiology, 2012, 184, 55-59.	0.7	10
256	Metabolic exercise data combined with cardiac and kidney indexes: MECKI score. Predictive role in cardiopulmonary exercise testing with low respiratory exchange ratio in heart failure. International Journal of Cardiology, 2015, 184, 299-301.	0.8	10
257	ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism. European Heart Journal Supplements, 2017, 19, D309-D332.	0.0	10
258	Heart rate during exercise: mechanisms, behavior, and therapeutic and prognostic implications in heart failure patients with reduced ejection fraction. Heart Failure Reviews, 2018, 23, 537-545.	1.7	10
259	Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology. European Journal of Internal Medicine, 2022, 102, 8-16.	1.0	10
260	Noninvasive Estimation of the Lactate Threshold in a Subject With Dissociated Ventilatory and Pulmonary Gas Exchange Indices. Chest, 2007, 132, 1994-1997.	0.4	9
261	Inside ventilatory regulation in pulmonary hypertension: several hidden data are still undiscovered. European Journal of Preventive Cardiology, 2014, 21, 268-271.	0.8	9
262	Management of heart failure in the new era. Journal of Cardiovascular Medicine, 2016, 17, 569-580.	0.6	9
263	Improvement in exercise capacity and delayed anaerobic metabolism induced by far-infrared-emitting garments in active healthy subjects: A pilot study. European Journal of Preventive Cardiology, 2018, 25, 1744-1751.	0.8	9
264	Exertional Periodic Breathing in Heart Failure. Clinics in Chest Medicine, 2019, 40, 449-457.	0.8	9
265	Immature surfactant protein-B impairs the antioxidant capacity of HDL. International Journal of Cardiology, 2019, 285, 53-58.	0.8	9
266	Multiplexed MRM-Based Proteomics Identified Multiple Biomarkers of Disease Severity in Human Heart Failure. International Journal of Molecular Sciences, 2021, 22, 838.	1.8	9
267	Exercise oscillatory breathing in heart failure with reduced ejection fraction: clinical implication. European Journal of Preventive Cardiology, 2022, 29, 1692-1698.	0.8	9
268	Pleural liquid pressure at the caudal border of the lung. Respiration Physiology, 1989, 75, 117-128.	2.8	8
269	Exercise Performance in Patients with Uncomplicated Essential Hypertension. Chest, 1992, 101, 1591-1596.	0.4	8
270	Monitoring gas exchange during a constant work rate exercise in patients with left ventricular dysfunction treated with carvedilol. American Journal of Cardiology, 2000, 85, 660-664.	0.7	8

#	Article	IF	Citations
271	Alveolar-capillary gas exchange and exercise performance in heart failure. American Journal of Cardiology, 2001, 88, 452-457.	0.7	8
272	Exercise-induced changes in exhaled nitric oxide in heart failure. European Journal of Heart Failure, 2004, 6, 551-554.	2.9	8
273	Cardiopulmonary exercise test evidence of isolated right coronary artery disease. International Journal of Cardiology, 2006, 113, 281-282.	0.8	8
274	Opposite behavior of plasma levels surfactant protein type B and receptor for advanced glycation end products in pulmonary sarcoidosis. Respiratory Medicine, 2013, 107, 1617-1624.	1.3	8
275	Exercise performance, haemodynamics, and respiratory pattern do not identify heart failure patients who end exercise with dyspnoea from those with fatigue. ESC Heart Failure, 2018, 5, 115-119.	1.4	8
276	Heart failure and sleep related breathing disorders: Data from PROMISES (Progetto Multicentrico) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.8	8
277	Upward Shift and Steepening of the Blood Pressure Response to Exercise in Hypertensive Subjects at High Altitude. Journal of the American Heart Association, 2018, 7, .	1.6	8
278	Ghrelin Derangements in Idiopathic Dilated Cardiomyopathy: Impact of Myocardial Disease Duration and Left Ventricular Ejection Fraction. Journal of Clinical Medicine, 2019, 8, 1152.	1.0	8
279	Sacubitril/valsartan can improve exercise performance in systolic chronic heart failure patients: a case report. Current Medical Research and Opinion, 2019, 35, 3-5.	0.9	8
280	Evidence of a double anaerobic threshold in healthy subjects. European Journal of Preventive Cardiology, 2022, 29, 502-509.	0.8	8
281	Cardiovascular Death Risk in Recovered Mid-Range Ejection Fraction Heart Failure: Insights From Cardiopulmonary Exercise Test. Journal of Cardiac Failure, 2020, 26, 932-943.	0.7	8
282	The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner?. European Respiratory Journal, 2022, 60, 2102276.	3.1	8
283	Continuous Ultrafiltration in Acute Decompensated Heart Failure: Current Issues and Future Directions. American Journal of Cardiovascular Drugs, 2015, 15, 103-112.	1.0	7
284	Do rebreathing manoeuvres for non-invasive measurement of cardiac output during maximum exercise test alter the main cardiopulmonary parameters?. European Journal of Preventive Cardiology, 2019, 26, 1616-1622.	0.8	7
285	Minute ventilation/carbon dioxide production in chronic heart failure. European Respiratory Review, 2021, 30, 200141.	3.0	7
286	Continuous ultrafiltration for congestive heart failure: the CUORE trial. Journal of Cardiac Failure, 2014, 20, 378.e1-9.	0.7	7
287	Matrix metalloproteinase and heart failure: is it time to move from research to clinical laboratories?. European Heart Journal, 2007, 28, 659-660.	1.0	6
288	NT-proAtrial Natriuretic Peptide as a possible biomarker of cardiopulmonary involvement in sarcoidosis. European Journal of Internal Medicine, 2013, 24, 278-284.	1.0	6

#	Article	IF	Citations
289	Exertional dyspnoea in cardiorespiratory disorders: the clinical use of cardiopulmonary exercise testing. European Respiratory Review, 2016, 25, 227-229.	3.0	6
290	Roles of periodic breathing and isocapnic buffering period during exercise in heart failure. European Journal of Preventive Cardiology, 2020, 27, 19-26.	0.8	6
291	Cardiac output changes during exercise in heart failure patients: focus on midâ€exercise. ESC Heart Failure, 2021, 8, 55-62.	1.4	6
292	Validation of a new wearable device for type 3 sleep test without flowmeter. PLoS ONE, 2021, 16, e0249470.	1.1	6
293	Exercise training effects on metabolic and ventilatory changes in heart failure patients with exercise oscillatory ventilation: systematic review and meta-analysis. European Journal of Preventive Cardiology, 2022, 29, e233-e236.	0.8	6
294	Exercise oxygen pulse kinetics in patients with hypertrophic cardiomyopathy. Heart, 2022, 108, 1629-1636.	1.2	6
295	Machine learning for prediction of in-hospital mortality in coronavirus disease 2019 patients: results from an Italian multicenter study. Journal of Cardiovascular Medicine, 2022, 23, 439-446.	0.6	6
296	Influence of ACE-inhibition on salt-mediated worsening of pulmonary gas exchange in heart failure. British Journal of Clinical Pharmacology, 2001, 51, 482-487.	1.1	5
297	Rationale, experimental data, and emerging clinical evidence on early and preventive use of levosimendan in patients with ventricular dysfunction. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 310-316.	1.4	5
298	Effects of left ventricular assist device on cardiopulmonary exercise performance. European Journal of Heart Failure, 2020, 22, 381-382.	2.9	5
299	A Breathtaking Lift: Sex and Body Mass Index Differences in Cardiopulmonary Response in a Large Cohort of Unselected Subjects with Acute Exposure to High Altitude. High Altitude Medicine and Biology, 2021, 22, 379-385.	0.5	5
300	Feasibility of remote home monitoring with a T-shirt wearable device in post-recovery COVID-19 patients. Journal of Cardiovascular Medicine, 2021, 22, 860-863.	0.6	5
301	Why Levosimendan Improves the Clinical Condition of Patients With Advanced Heart Failure: A Holistic Approach. Journal of Cardiac Failure, 2022, 28, 509-514.	0.7	5
302	The Impact of Cardiac Rehabilitation on Activities of Daily Life in Elderly Patients With Heart Failure. Frontiers in Physiology, 2021, 12, 785501.	1.3	5
303	The double anaerobic threshold in heart failure. International Journal of Cardiology, 2022, 353, 68-70.	0.8	5
304	Sensitivity and specificity of different exercise oscillatory ventilation definitions to predict 2-year major adverse cardiovascular outcomes in chronic heart failure patients. International Journal of Cardiology, 2022, 360, 39-43.	0.8	5
305	Cardiopulmonary exercise testing in syndrome X. American Heart Journal, 1993, 125, 711-717.	1.2	4
306	Longâ€term use of Kâ€strophanthin in advanced congestive heart failure due to dilated cardiomyopathy: A doubleâ€blind crossover evaluation versus digoxin. Clinical Cardiology, 1994, 17, 536-541.	0.7	4

#	Article	IF	Citations
307	Evolving Role of Cardiopulmonary Exercise Testing in Heart Failure and Cardiac Transplantation. , 2002, 32, 99-108.		4
308	Delayed Anaerobic Threshold in Heart Failure Patients With Atrial Fibrillation. Journal of Cardiopulmonary Rehabilitation and Prevention, 2016, 36, 174-179.	1.2	4
309	ACE-Inhibition Benefit on Lung Function in Heart Failure is Modulated by ACE Insertion/Deletion Polymorphism. Cardiovascular Drugs and Therapy, 2016, 30, 159-168.	1.3	4
310	Cardiopulmonary Exercise Testing. Annals of the American Thoracic Society, 2017, 14, S1-S2.	1.5	4
311	ST2 and Bâ€type natriuretic peptide kinetics during exercise in severe heart failure. European Journal of Heart Failure, 2018, 20, 1494-1495.	2.9	4
312	Inside OUES: fact or fiction?. European Journal of Preventive Cardiology, 2019, 26, 174-176.	0.8	4
313	Effects of Î²2-receptor stimulation by indacaterol in chronic heart failure treated with selective or non-selective Î²-blockers: a randomized trial. Scientific Reports, 2020, 10, 7101.	1.6	4
314	In-Depth AGE and ALE Profiling of Human Albumin in Heart Failure: Ex Vivo Studies. Antioxidants, 2021, 10, 358.	2.2	4
315	Rest and exercise oxygen uptake and cardiac output changes 6Âmonths after successful transcatheter mitral valve repair. ESC Heart Failure, 2021, 8, 4915-4924.	1.4	4
316	Extracorporeal Fluid Removal in Heart Failure Patients. Contributions To Nephrology, 2010, 164, 173-198.	1.1	3
317	Recent myocardial infarction patients present ventilatory limitation during aerobic exercise. International Journal of Cardiology, 2012, 161, 180-181.	0.8	3
318	Effects of carvedilol on oxygen uptake and heart rate kinetics in patients with chronic heart failure at simulated altitude. European Journal of Preventive Cardiology, 2012, 19, 444-451.	0.8	3
319	Exercise ventilatory inefficiency in heart failure: some fresh news into the roadmap of heart failure with preserved ejection fraction phenotyping. European Journal of Heart Failure, 2017, 19, 1686-1689.	2.9	3
320	The Wrong Drug That Led to the Right Diagnosis. Circulation, 2019, 140, 1601-1604.	1.6	3
321	Variability in pulmonary diffusing capacity in heart failure. Respiratory Physiology and Neurobiology, 2020, 280, 103473.	0.7	3
322	Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort Study . Journal of Pragmatic and Observational Research, 2020, Volume 11, 55-66.	1.1	3
323	A new pathophysiology in heart failure patients. Artificial Organs, 2020, 44, 1303-1305.	1.0	3
324	Relationship between ventilatory pattern and peak VO2 and area M regulates the respiratory system during exercise. Journal of Cardiology, 2020, 76, 521-528.	0.8	3

#	Article	IF	Citations
325	Immature Circulating SP-B, Bound to HDL, Represents an Early Sign of Smoke-Induced Pathophysiological Alterations. Biomolecules, 2021, 11, 551.	1.8	3
326	Comparison of cardiovascular risk factors among coronary artery bypass graft patients in 2010 and 2016: A single-center study in Guilan province, Iran. ARYA Atherosclerosis, 2018, 14, 205-211.	0.4	3
327	OUP accepted manuscript. European Journal of Preventive Cardiology, 2022, , .	0.8	3
328	The double anaerobic threshold in heart failure: MECKI score database overview. ESC Heart Failure, 2022, 9, 2119-2124.	1.4	3
329	Vagal Cooling and Positive End-Expiratory Pressure Reduce Systemic to Pulmonary Bronchial Blood Flow in Dogs. Respiration, 1990, 57, 85-89.	1.2	2
330	Systemic to Pulmonary Bronchial Blood Flow in Mitral Stenosis*. Chest, 1991, 99, 642-645.	0.4	2
331	Influence of ACE Inhibition on Fluid Metabolism in Chronic Heart Failure and Its Pathophysiologic Relevance. Journal of Cardiovascular Pharmacology and Therapeutics, 1996, 1, 279-286.	1.0	2
332	Ultrafiltration for congestive heart failure. Current Opinion in Cardiology, 2015, 30, 186-191.	0.8	2
333	Exercise capacity is not impaired after acute alcohol ingestion. Journal of Cardiovascular Medicine, 2016, 17, 896-901.	0.6	2
334	Incremental utility of prognostic variables at discharge for risk prediction in hospitalized patients with acutely decompensated chronic heart failure. Heart and Lung: Journal of Acute and Critical Care, 2016, 45, 212-219.	0.8	2
335	Diving and pulmonary physiology: Surfactant binding protein, lung fluid and cardiopulmonary test changes in professional divers. Respiratory Physiology and Neurobiology, 2017, 243, 27-31.	0.7	2
336	Left atrium and pulmonary vein imaging using sub-millisiviert cardiac computed tomography: Impact on radiofrequency catheter ablation cumulative radiation exposure and outcome in atrial fibrillation patients. International Journal of Cardiology, 2017, 228, 805-811.	0.8	2
337	2D speckle tracking echocardiography of the right ventricle free wall in <scp>SCUBA</scp> divers after single open sea dive. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 234-240.	0.9	2
338	A medicine for tall, white, blond-haired and blue-eyed, middle-aged, physically active, rich males?. European Journal of Preventive Cardiology, 2018, 25, 1152-1155.	0.8	2
339	Prediction of peak oxygen uptake by an endurance test: A wish and a nightmare. European Journal of Preventive Cardiology, 2020, 27, 2042-2044.	0.8	2
340	Chemoreceptor hyperactivity in heart failure: Is lactate the culprit?. European Journal of Preventive Cardiology, 2020, 28, e8-e10.	0.8	2
341	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. Journal of Healthcare Engineering, 2021, 2021, 1-10.	1.1	2
342	Listing Criteria for Heart Transplant. Heart Failure Clinics, 2021, 17, 635-646.	1.0	2

#	Article	IF	Citations
343	Continuous positive airway pressure in cardiovascular medicine. Journal of Cardiovascular Medicine, 2014, 15, 361-363.	0.6	1
344	Left ventricular function and exercise performance in idiopathic dilated cardiomyopathy. Journal of Cardiovascular Medicine, 2017, 18, 230-236.	0.6	1
345	Exertional Oscillatory Ventilation and Central Sleep Apnea in Heart Failure: Siblings, Cousins, or What Else?. , 2017, , 183-202.		1
346	Natriuretic peptide B plasma concentration increases in the first 12â€¯h of pulmonary edema recovery. European Journal of Internal Medicine, 2018, 53, 52-56.	1.0	1
347	The MECKI score initiative: a successful and ongoing story. European Journal of Preventive Cardiology, 2020, 27, 3-4.	0.8	1
348	Does PAP/CO Ratio Have a Linear Relationship?. Journal of the American College of Cardiology, 2020, 75, 2646.	1.2	1
349	Lung function evaluation in heart failure: possible pitfalls. Breathe, 2020, 16, 190316.	0.6	1
350	Exercise Dynamic of Patients with Chronic Heart Failure and Reduced Ejection Fraction. Current Cardiology Reports, 2021, 23, 92.	1.3	1
351	Week to week variability of pulmonary capillary blood volume and alveolar membrane diffusing capacity in patients with heart failure. Respiratory Physiology and Neurobiology, 2021, 290, 103679.	0.7	1
352	Patterns of cardiopulmonary response to exercise in cardiac diseases. , 0, , 146-159.		1
353	Can Î²-blockers influence regular daily physical activity?. Journal of Hypertension, 2022, 40, 1199-1203.	0.3	1
354	Hemodynamic Response to Oral Prenalterol in Dilated Decompensated Cardiomyopathy as a Result of Cardiac and Vascular Effects. Angiology, 1985, 36, 857-866.	0.8	0
355	Ineffectiveness of angiotensin converting enzyme inhibition (enalapril) on overt and silent myocardial ischemia in vasospastic angina and comparison with verapamil*. Clinical Pharmacology and Therapeutics, 1996, 59, 476-481.	2.3	0
356	Exercise-induced cardiac costraint by the lungs. Respiratory Medicine CME, 2009, 2, 33-35.	0.1	0
357	â€œBeyond the ventilationâ€: a reply to the letter to the editor of A. M. Ferrazza and P. Palange. European Journal of Applied Physiology, 2009, 105, 979-980.	1.2	0
358	Reactive Pulmonary Hypertension in Heart Failure is Another Disease Identified by Cardiopulmonary Exercise Test. Journal of Cardiac Failure, 2014, 20, 658-661.	0.7	0
359	Reply to commentary on: Confusion in reporting pulmonary diffusion capacity for nitric oxide and the alveolar-capillary membrane conductance for nitric oxide. European Journal of Preventive Cardiology, 2015, 22, 314-316.	0.8	0
360	Prognostic implications of heart failure with preserved ejection fraction in patients with an exacerbation of chronic obstructive pulmonary disease. Internal and Emergency Medicine, 2016, 11, 517-518.	1.0	0

#	Article	IF	Citations
361	The â€œhands-onâ€•patient-centered method: An old approach for a new perspective in acute heart failure. International Journal of Cardiology, 2017, 245, 213-214.	0.8	0
362	One-size-fits-all peak VO 2 , a dream or a nightmare. International Journal of Cardiology, 2018, 263, 94-95.	0.8	0
363	Why do left ventricular assist device recipients remain heart failure patients? Reply. European Journal of Heart Failure, 2020, 22, 1055-1055.	2.9	0
364	Late Breaking Abstract - Characteristics and treatment of patients with comorbid COPD and heart failure. , 2018, , .		0
365	OUP accepted manuscript. European Journal of Preventive Cardiology, 2022, , .	0.8	0
366	Pulmonary hemodynamic and tidal volume changes during exercise in heart failure. Italian Heart Journal: Official Journal of the Italian Federation of Cardiology, 2002, 3, 104-8.	0.1	0